Scholarlink

<p>This is a summary of the original article “Safety and effectiveness of concomitant iGlarLixi and SGLT-2i use in people with T2D during Ramadan fasting: a SoliRam study sub-analysis.” iGlarLixi is a fixed-ratio combination of insulin glargine 100&#xa0;U/ml and glucagon like peptide&#xa0;1 receptor agonist (GLP-1RA) lixisenatide which has demonstrated its effectiveness of improving glycemic parameters and reducing body weight with low risk of hypoglycemia incidence in adults with type&#xa0;2 diabetes (T2D) who were previously sub-optimally controlled with oral antidiabetic drugs (OADs) alone or in combination with basal insulin or GLP-1RA. This sub-analysis of the SoliRam study assessed the safety and effectiveness of concomitant iGlarLixi and sodium/glucose cotransporter&#xa0;2 (SGLT-2i) use with or without other OADs in adults with T2D who fasted during Ramadan. Participants were divided into two groups: SGLT-2i-users and SGLT-2i-non-users. The findings showed low incidence of severe and/or symptomatic documented hypoglycemia, improved glycemic control, and body weight benefits, irrespective of SGLT-2i use. No serious adverse events were reported in either group. The sub-analysis concluded that the concomitant iGlarLixi and SGLT-2i therapy, with or without other OADs, was demonstrated to be a safe treatment for people with T2D during Ramadan fasting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Mohamed Hassanein,
  • Rachid Malek,
  • Saud Al Sifri,
  • Rakesh Kumar Sahay,
  • Mehmet Akif Buyukbese,
  • Khier Djaballah,
  • Lydie Melas-Melt,
  • Inass Shaltout

摘要

This is a summary of the original article “Safety and effectiveness of concomitant iGlarLixi and SGLT-2i use in people with T2D during Ramadan fasting: a SoliRam study sub-analysis.” iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/ml and glucagon like peptide 1 receptor agonist (GLP-1RA) lixisenatide which has demonstrated its effectiveness of improving glycemic parameters and reducing body weight with low risk of hypoglycemia incidence in adults with type 2 diabetes (T2D) who were previously sub-optimally controlled with oral antidiabetic drugs (OADs) alone or in combination with basal insulin or GLP-1RA. This sub-analysis of the SoliRam study assessed the safety and effectiveness of concomitant iGlarLixi and sodium/glucose cotransporter 2 (SGLT-2i) use with or without other OADs in adults with T2D who fasted during Ramadan. Participants were divided into two groups: SGLT-2i-users and SGLT-2i-non-users. The findings showed low incidence of severe and/or symptomatic documented hypoglycemia, improved glycemic control, and body weight benefits, irrespective of SGLT-2i use. No serious adverse events were reported in either group. The sub-analysis concluded that the concomitant iGlarLixi and SGLT-2i therapy, with or without other OADs, was demonstrated to be a safe treatment for people with T2D during Ramadan fasting.